Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant

Clin Transpl. 2009:439-41.

Abstract

Bortezomib can be used to successfully treat acute kidney injury in the renal transplant allograft due to light chain cast nephropathy from recurrent multiple myeloma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use
  • Biopsy
  • Bone Marrow / immunology
  • Bone Marrow / pathology
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Female
  • Humans
  • Immunoglobulin kappa-Chains / analysis
  • Immunosuppressive Agents / therapeutic use
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / pathology
  • Living Donors
  • Multiple Myeloma / complications*
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Protease Inhibitors / therapeutic use*
  • Pyrazines / therapeutic use*
  • Recurrence
  • Syndecan-1 / analysis
  • Tacrolimus / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Boronic Acids
  • Immunoglobulin kappa-Chains
  • Immunosuppressive Agents
  • Protease Inhibitors
  • Pyrazines
  • Syndecan-1
  • Alemtuzumab
  • Bortezomib
  • Mycophenolic Acid
  • Tacrolimus